The time to develop treatments for diabetic neuropathy

Area of Science:

• Neurology
• Endocrinology
• Pharmacology

Background:

• Diabetic neuropathy affects up to 50% of individuals with long-standing diabetes.
• Peripheral diabetic sensory neuropathy (DPN) is the most common form.
• Current treatments primarily manage pain, not the underlying pathology.

Purpose of the Study:

• To review the history of treatment trials for diabetic neuropathy.
• To identify challenges in developing effective DPN therapies.
• To propose regulatory modifications for drug approval.

Main Methods:

• Systematic literature review of PubMed and targeted Google searches.
• Inclusion of terms related to neuropathy types, diagnostic methods, and therapeutic agents.
• Analysis of past clinical trial outcomes and regulatory hurdles.

Main Results:

• Numerous agents have failed in clinical trials over the past 50 years.
• Approved medications offer symptomatic relief but do not halt disease progression.
• Challenges include intricate study designs and the slow, progressive nature of DPN.

Conclusions:

• Treatment development for DPN is hindered by study design complexity and slow disease progression.
• A modified regulatory process could facilitate earlier introduction of safe, potentially beneficial agents.
• Prolonging marketing exclusivity may incentivize long-term efficacy trials.